Results 71 to 80 of about 22,543 (220)

Positioning new pharmacotherapies for COPD

International Journal of COPD, 2015
Igor Z Barjaktarevic,1 Anthony F Arredondo,1 Christopher B Cooper1,2 1Department of Medicine, 2Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA Abstract: COPD imposes ...
Barjaktarevic IZ, Arredondo AF, Cooper CB   +2 more
doaj  

Muscarinic antagonists impair multiple aspects of operant discrimination learning and performance. [PDF]

Neurosci Lett, 2023
Yousuf H, Girardi EM, Crouse RB, Picciotto MR.   +3 more
europepmc   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, EarlyView.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source

Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol

International Journal of COPD, 2014
Mario Malerba,1 Jaymin Bhagwanji Morjaria,2 Alessandro Radaeli3 1Department of Internal Medicine, University of Brescia, Brescia, Italy; 2Department of Academic Respiratory Medicine, Hull York Medical School, University of Hull, Castle Hill Hospital ...
Malerba M, Morjaria JB, Radaeli A
doaj  

Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. [PDF]

Cochrane Database Syst Rev, 2023
van Geffen WH, Tan DJ, Walters JA, Walters EH.   +3 more
europepmc   +1 more source

Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5‐HT2A receptor

British Journal of Pharmacology, EarlyView.
A pharmacological profiling of 58 synthetic stimulants of various classes at dopamine, norepinephrine, and serotonin transporters and the 5‐HT2A receptor, most showing distinct class‐dependent profiles, with some indicating a high abuse potential. Background and Purpose New psychoactive substances (NPSs) often emerge on the illicit drug market with ...
Darta Stalberga, Robert Kronstrand, Bianca Schranz, Nick van Zijl, Sebastian Karlman, Soma Aref, Tobias Rautio, Svante Vikingsson, Mattias Persson, Henrik Green   +9 more
wiley   +1 more source

Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium. [PDF]

BMC Pulm Med, 2022
Katsumata M, Fujisawa T, Kamiya Y, Tanaka Y, Kamiya C, Inoue Y, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Maekawa M, Setou M, Watanabe H, Ikegami K, Suda T.   +17 more
europepmc   +1 more source

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. [PDF]

Eur Respir Rev, 2022
Calzetta L, Ritondo BL, Zappa MC, Manzetti GM, Perduno A, Shute J, Rogliani P.   +6 more
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma. [PDF]

Ann Am Thorac Soc, 2022
Krishnan JA, Lazarus SC, Blake KV, Sorkness CA, Covar R, Dyer AM, Lang JE, Lugogo NL, Mauger DT, Wechsler ME, Wenzel SE, Cardet JC, Castro M, Israel E, Phipatanakul W, King TS.   +15 more
europepmc   +1 more source